BI 1479-0012 (Beamion BCGC-1): A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) Alone or in Combination With Other Agents for the Treatment of Patients With Advanced HER2+ Metastatic Breast Cancer (mBC), Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC), or Metastatic Colorectal Cancer (mCRC)

Objective

Clinical Trial Details

Principal Investigator(s)

Jason Jones, MD

Clinical Trial Categories

• Cancer
• Breast Cancer
• Colorectal Cancer
• Esophageal/Gastroesophageal Junction (GEJ)

Contact

Breast Research Coordinators at 605-322-1432
or breastresearch@avera.org